BioMAP profiling using primary human cell models can rapidly characterize drug mechanisms and off-target effects relevant to vascular inflammation, potentially explaining clinical phenomena like reduced posttransplant cardiovascular disease with mycophenolic acid.
No takes yet. Share an insight, caveat, or question.
May elucidate off-target cardiovascular drug effects; hypothesis-generating from cell models and requires clinical validation.
Kunkel et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: